GlassScriptPhysician profile
Dmitri Kirpichnikov
NPI 1982659660
$2,493.35
in general payments reported to CMS, 2019-2025
17 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $402 · 2021: $398 · 2022: $542 · 2023: $509 · 2024: $210 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $682.26 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $407.49 | 2019-2021 | |
| Abbvie INC. | $387.33 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.21 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $174.71 | 2021-2023 | Ozempic, Rybelsus |
| Amgen INC. | $156.00 | 2021-2025 | Evenity, Prolia, Prolia |
| Amarin Pharma, INC. | $152.02 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $129.35 | 2019-2023 | Verquvo, Steglatro |
| Sanofi-Aventis U.S. LLC | $47.52 | 2020 | |
| Janssen Biotech, INC. | $25.90 | 2025 | Tremfya |
| Lilly USA, LLC | $25.00 | 2023 | Jardiance |
| Esperion Therapeutics, INC. | $24.98 | 2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $24.00 | 2020 | |
| Avanir Pharmaceuticals, INC. | $21.94 | 2019 | |
| Avion Pharmaceuticals | $20.27 | 2023 | NP Thyroid 60 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17.49 | 2022 | |
| Insulet Corporation | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitri Kirpichnikov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.